Article

Apoptosis not only culprit in cell death

Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.

New Orleans-Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.

Alternative pathways are also at work, said Dr. Miller, chief and chairwoman, Department of Ophthalmology, Massachusetts Eye and Ear, Boston.   

Past research has focused on the mechanisms of cell death in the hopes of identifying therapeutic targets in degenerative retinal disease.

Previously, Dr. Miller said, apoptosis was thought to be the main mechanism of photoreceptor degeneration, but research shows it is not.

“Indeed, the caspase enzymes-which play a central role for inducing apoptosis-are activated in dying photoreceptor cells in experimental modes,” Dr. Miller said. “Paradoxically, inhibiting caspases doesn’t sufficiently protect against cell loss.”

Dr. Miller pointed out the involvement of other cell death mechanisms-specifically mentioning accumulating evidence demonstrating nonapoptotic forms of cell death, such as autophagy and necrosis, which are also regulated by specific molecular machinery, such as autophangy-related proteins and receptor-interacting protein RIP kinases, respectively.

“Certainly there are different pathogenesis,” she said. “There are different pathways, redundant and complimentary, for all these different diseases and some are overlapping.”

The key point, she said, is a research focus on combination therapy in order to achieve neuroprotection. By identifying alternative cell death pathways and understanding how to inhibit them, we can prevent vision loss in multiple eye disorders.

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.